Status:
COMPLETED
Evaluation of PD-L1 (Programmed Death-Ligand 1) Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC)
Lead Sponsor:
Groupe Francais De Pneumo-Cancerologie
Conditions:
Large Cell Lung Cancer
Neuroendocrine Carcinoma of Lung (Diagnosis)
Eligibility:
All Genders
18+ years
Brief Summary
Observational, multicentre, retrospective study on patients taken care according to the national guidelines. The objective is to define, after the diagnosis confirmation, the frequency of PD-L1 expres...
Eligibility Criteria
Inclusion
- Patients aged \> or = 18 years
- Diagnosis of Large-cell NEC confirmed by centralised reading
- Tumoral materials available and readable for PD-L1 labeling
Exclusion
- Other type of Lung cancers
- Tumoral material not available or not readable for centralised reading
- Tumoral material not available or not readable for PD-L1 labeling
Key Trial Info
Start Date :
September 26 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 30 2018
Estimated Enrollment :
86 Patients enrolled
Trial Details
Trial ID
NCT03305133
Start Date
September 26 2017
End Date
October 30 2018
Last Update
March 12 2020
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier D Argenteuil
Argenteuil, VAL D'oise, France, 95100
2
Site 12
Aix-en-Provence, France, 13100
3
Centre Hospitalier Universitaire
Angers, France, 49033
4
Site 05
Bastia, France, 20200